We currently have two stock-based compensation plans, the Second Amended and Restated Employee Stock Purchase Plan (the "ESPP") and the Fourth Amended and Restated 2014 Equity Incentive Plan (the "Fourth Amended 2014 Plan"). Our ESPP provides that we may issue up to 500,000 shares of our common stock under the plan. Our Fourth Amended 2014 Plan provides that we may grant equity awards representing up to 5,750,000 options on or shares of our common stock to members of our Board of Directors, employees, consultants and advisors. The Fourth Amended 2014 Plan was approved by our shareholders in May 2019. As of June 30, 2026, 32,918 shares remained available for issuance under the ESPP and 1,661,591 shares remained available for issuance under the Fourth Amended 2014 Plan.

Exercises and vesting under our stock-based compensation plans resulted in no income tax-related charges to paid-in capital during the three and six months ended June 30, 2026 and 2025.

Restricted Stock and Restricted Stock Units

During the three and six months ended June 30, 2026 and 2025, we granted (net of forfeitures) of 5,813, 232,465, 65,411 and 74,414 shares of restricted stock and restricted stock units, respectively, with aggregate grant date fair values of $0.4 million, $12.6 million, $3.4 million and $3.8 million, respectively. We incurred expenses of $2.8 million, $4.2 million, $0.9 million and $1.8 million during the three and six months ended June 30, 2026 and 2025, respectively, related to restricted stock awards. When we grant restricted stock and restricted stock units, we defer the grant date value of the restricted stock and restricted stock unit and amortize that value (net of the value of anticipated forfeitures) as compensation expense with an offsetting entry to the paid-in capital component of our condensed consolidated shareholders’ equity. Our restricted stock awards typically vest over a range of 12 to 60 months (or other term as specified in the grant which may include the achievement of performance measures) and are amortized to salaries and benefits expense ratably over applicable vesting periods. As of June 30, 2026, our unamortized deferred compensation costs associated with non-vested restricted stock awards were $17.4 million with a weighted-average remaining amortization period of 2.7 years. No forfeitures have been included in our compensation cost estimates based on historical forfeiture rates.

The table below includes additional information about outstanding restricted stock and restricted stock units:

Stock Options

The exercise price per share of the options awarded under the Fourth Amended 2014 Plan must be equal to or greater than the market price on the date the option is granted. The option period may not exceed 10 years from the date of grant. There has been no expense related to stock option-related compensation costs in 2026 and 2025. When applicable, we recognize stock option-related compensation expense for any awards with graded vesting on a straight-line basis over the vesting period for the entire award. The table below includes additional information about outstanding options:

No options were issued during the three and six months ended June 30, 2026 and 2025. We had no unamortized deferred compensation costs associated with non-vested stock options at both  June 30, 2026 and December 31, 2025. Upon exercise of outstanding options, the Company issues new shares.